Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients

Clinical Therapeutics

Volumn 30, Issue 2, 2008, Pages 372-381

  Sánchez de la Rosa, Rainel ^a   Herrera, Luis ^a   Moreno, Santiago ^b  

^a GILEAD SCIENCES   (United States)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

cost analysis; HAART; HIV 1; nucleoside analogue reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMATURIA; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERAMYLASEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL; RASH; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VOMITING;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COST-BENEFIT ANALYSIS; DECISION TREES; DEOXYCYTIDINE; DRUG COSTS; HEALTH CARE COSTS; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MODELS, ECONOMIC; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 41549161098     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.02.009     Document Type: Article

References (24)

1. Panel de Expertos de GESIDA and the Plan Nacional Sobre el Sida. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007) [in Spanish]. Enferm Infecc Microbiol Clin 25 (2007) 32-53
2. Robbins G., De Gruttola V., Shafer R., et al., AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349 (2003) 2293-2303
3. Bozzette S., Joyce G., McCaffrey D., et al., HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly antiretroviral therapy. N Engl J Med 344 (2001) 817-823
4. Chapman T., McGavin J., and Noble S. Tenofovir disoproxil fumarate. Drugs 63 (2003) 1597-1608
5. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [US Dept of Health and Human Services Web site]. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf Accessed October 2007
6. DeJesus E., Herrera G., Teofilo E., et al., CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive, HIV-infected adults. Clin Infect Dis 39 (2004) 1038-1046
7. Staszewski S., Morales-Ramirez J., Tashima K., et al., Study 006 Team. Efavirenz plus zidovudine and la-mivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341 (1999) 1865-1873
8. Gallant J., DeJesus E., Arribas J., et al., Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zido-vudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
9. Arribas J., Pozniak A., Gallant J., et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-Week analysis. J Acquir Immune Defic Syndr 47 (2008) 74-78
10. Pozniak A., Gallant J., DeJesus E., et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologie, immunologie, and morphologie changes class-a 96-week analysis. J Acquir Immune Defic Syndr 43 (2006) 535-540
11. Rietmeijer C., Davidson A., Foster C., and Cohn D. Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. Arch Intern Med 153 (1993) 219-225
12. Llibre-Codina J., Casado-Gomez M., Sanchez-de la Rosa R., et al. Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients [in Spanish]. Enferm InfeccMicrobiol Clin 25 (2007) 98-107
13. Ridao M., and Peiró S. Introducción a la evaluación económica. Instituto Valenciano de Estudios para Salud Pública 1 (1996) 7
14. Rovira J., and Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 8 (1995) 245-252
15. Boletín Oficial del Estado. Real Decreto 2388/2004 of 30 December. http://www.mtas.es/fogasa/normativas/complementaria/nc63
16. Colegio Oficial de Farmacéuticos. Catálogo General de Especialidades Farmacéuticas (2006)
17. Real Decreto 2402/2004, de 30 de diciembre, por el que se desarrolla el artículo 104 de la Ley 25/1990, de 20 de diciembre, del Medicamento, para las revisiones coyunturales de precios de especialidades farmacéuticas y se adoptan medidas adicionales para la contención del gasto farmacéutico. http://www.noticias.juridicas.com/base_datos/Admin/rd2404-2004.html Accessed October 28, 2007
18. Data from SOIKOS Spanish Costs Data Base: SOIKOS (2005)
19. UNAIDS/WHO (2005). AIDS Epidem-ic Update. UNAIDS/WHO, Geneva. http://w3.whosea.org/EN/Section10/Section18/Section348.htm
20. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53 (2004) 558-561
21. Revicki D., and Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. PharmacoEconomics 15 (1999) 423-434
22. Lichtenstein K., Ward D., Moorman A., et al., HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001) 1389-1398
23. Oliva J., Roa C., and del Llano J. Indirect costs in ambulatory patients with HIV/AIDS in Spain: A pilot study. PharmacoEconomics 21 (2003) 1113-1121
24. Messori A., Becagli P., Berto V., et al., Osservatorio SIFO sui Farmaci. Advanced HIV infection treated with zidovudine monotherapy: Lifetime values of absolute cost-effectiveness zas a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. Ann Pharmacother 31 (1997) 1447-1454